Case - Fungal Urosepsis After Ureteroscopy in a Patient on New Generation of Anti-hyperglycemic Medication

Overview

Journal Can Urol Assoc J

Specialty Urology

Date 2018 Nov 27

PMID 30472979

Authors

Hamidreza Abdi

Eric Locke

Ryan Fitzpatrick

Jeffery Stuart Oake

Affiliations

Soon will be listed here.

References

Perlroth J, Choi B, Spellberg B . Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007; 45(4):321-46. DOI: 10.1080/13693780701218689. View

Campbell R . Fate of the beta-cell in the pathophysiology of type 2 diabetes. J Am Pharm Assoc (2003). 2009; 49 Suppl 1:S10-5. DOI: 10.1331/JAPhA.2009.09076. View

Maalouf N, Cameron M, Moe O, Sakhaee K . Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010; 5(7):1277-81. PMC: 2893060. DOI: 10.2215/CJN.08331109. View

Grabe M, Botto H, Cek M, Tenke P, Wagenlehner F, Naber K . Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures. World J Urol. 2011; 30(1):39-50. DOI: 10.1007/s00345-011-0722-z. View

Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp D . Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2011; 14(1):83-90. DOI: 10.1111/j.1463-1326.2011.01517.x. View

Haring H, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle H . Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11):3396-404. PMC: 3816918. DOI: 10.2337/dc12-2673. View

Halimi S, Verges B . Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2015; 40(6 Suppl 1):S28-34. DOI: 10.1016/S1262-3636(14)72693-X. View

Gallo L, Wright E, Vallon V . Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015; 12(2):78-89. PMC: 5886707. DOI: 10.1177/1479164114561992. View

Mrkobrada M, Ying I, Mokrycke S, Dresser G, Elsayed S, Bathini V . CUA Guidelines on antibiotic prophylaxis for urologic procedures. Can Urol Assoc J. 2015; 9(1-2):13-22. PMC: 4336023. DOI: 10.5489/cuaj.2382. View

10.

Rao P . Aspergillus infection in urinary tract post-ureteric stenting. Indian J Med Microbiol. 2015; 33(2):316-8. DOI: 10.4103/0255-0857.154895. View

11.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

12.

Arakaki R . Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgrad Med. 2016; 128(4):409-17. DOI: 10.1080/00325481.2016.1167570. View

13.

Levine M . Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials. Curr Diabetes Rev. 2016; 13(4):405-423. PMC: 5543566. DOI: 10.2174/1573399812666160613113556. View

14.

Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H . Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2016; 19(3):348-355. DOI: 10.1111/dom.12825. View

15.

Thong K, Yadagiri M, Barnes D, Morris D, Ahmad Chowdhury T, Chuah L . Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Prim Care Diabetes. 2017; 12(1):45-50. DOI: 10.1016/j.pcd.2017.06.004. View

16.

Singh M, Kumar A . Risks Associated with SGLT2 Inhibitors: An Overview. Curr Drug Saf. 2018; 13(2):84-91. DOI: 10.2174/1574886313666180226103408. View